Melanoma trials in China
69 trials · From ClinicalTrials.gov, checked 11 November 2026. Ask the study team whether a trial fits you.
- Phase 1Enrolling by invitationA Trial of AK104 or AK112 in Combination With Axitinib in Patients With Metastatic Mucosal Melanoma
- Where
- Beijing
- Age
- 18 years and over
- People
- 60
- Run by
- Peking University Cancer Hospital & Institute
See details and how to joinNCT06424626 - Phase 2Taking peopleA Phase II Clinical Study of Multimodal Ablation Combined With Systemic Drug Therapy for Advanced Solid Tumors.
- Where
- Shanghai
- Age
- 18 years to 80 years
- People
- 95
- Run by
- Fudan University
See details and how to joinNCT06889610 - Phase 1Taking peopleA Clinical Study to Evaluate the Safety and Tolerability of AWT020 in Patients With Advanced Malignancies
- Where
- Changchun, Changsha, Fuzhou, Guangzhou, Hangzhou, Harbin, Kunming, Luoyang, Nanchang, Shanghai, Shenyang, Wuhan
- Age
- 18 years and over
- People
- 214
- Run by
- Shanghai Junshi Bioscience Co., Ltd.
See details and how to joinNCT06839105 - Phase 1Taking peopleA Study of DEG6498 in Participants With Solid Tumors
- Where
- Beijing, Guangzhou
- Age
- 18 years and over
- People
- 100
- Run by
- Degron Therapeutics Co.
See details and how to joinNCT07244835 - No phaseNot yet taking people in ChinaCLASSIFY-OMM: Multicenter Rare Disease Cohort for T-Stage Reclassification and Molecular Subtyping-Based Precision Therapy in Oral Mucosal Melanoma
- Where
- Shanghai
- Age
- 18 years and over
- People
- 1,100
- Run by
- Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
See details and how to joinNCT07662694 - Phase 2Taking peopleThymosin Alpha 1 Combined With Anti-PD-1 Monoclonal Antibody in Elderly Patients With Advanced Melanoma
- Where
- Guangzhou, Shenzhen
- Age
- 60 years and over
- People
- 55
- Run by
- Sun Yat-sen University
See details and how to joinNCT07644897 - Phase 1/2Taking peopleDual-Target CSPG4/GD2 CAR-NK Cells for Advanced Melanoma
- Where
- Shenzhen
- Age
- 18 years to 75 years
- People
- 36
- Run by
- Beijing Biotech
See details and how to joinNCT07627698 - No phaseTaking peopleExploratory Study With Parallel Controls on the Safety and Efficacy of Neoadjuvant Low Branched-Chain Amino Acid Diet in Combination With Anti-PD-1 Monoclonal Antibody for Stage III Melanoma
- Where
- Xi’an
- Age
- 18 years to 75 years
- People
- 80
- Run by
- Xijing Hospital
See details and how to joinNCT07586891 - Early phase 1Taking peopleEfficacy and Safety of Neoadjuvant Cadonilimab Plus High-Dose Recombinant Human Interferon α1b in Stage III/IV Melanoma.
- Where
- Xi'an
- Age
- 18 years to 75 years
- People
- 10
- Run by
- Xijing Hospital
See details and how to joinNCT07586904 - No phaseTaking peopleLiquid Biopsy Multi-Omics and Biomarker Development in Melanoma
- Where
- Xi’an
- Age
- 18 years to 80 years
- People
- 200
- Run by
- Xijing Hospital
See details and how to joinNCT07584291 - No phaseTaking peopleSub-topic Four: Clinical Translation of Original Radioactive Drugs for Precision Diagnosis and Treatment of Gastrointestinal Tumors -Clinical Application Value of PET Imaging Targeting LRRC15 in Malignant Tumors
- Where
- Wuhan
- Age
- 18 years and over
- People
- 26
- Run by
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
See details and how to joinNCT07552467 - Phase 1/2Taking peopleHX009+ IN10018 With or Without Standard Chemotherapy for Advanced Solid Tumours
- Where
- Beijing
- Age
- 18 years to 70 years
- People
- 124
- Run by
- Hangzhou Hanx Biopharmaceuticals, Ltd.
See details and how to joinNCT06708663 - Phase 4Taking peopleRWS of Tunlametinib in NRAS-Mutant Advanced Melanoma
- Where
- Shanghai
- Age
- 18 years and over
- People
- 110
- Run by
- Fudan University
See details and how to joinNCT07445022 - Phase 1/2Taking peopleBiomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors
- Where
- Beijing
- Age
- 8 years to 85 years
- People
- 85
- Run by
- Essen Biotech
See details and how to joinNCT07410494 - Phase 1/2Taking peopleEBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors
- Where
- Beijing
- People
- 83
- Run by
- Essen Biotech
See details and how to joinNCT07410676 - Phase 1Taking peopleA Phase 1 Study of TGI-5 as Monotherapy and in Combination With Nivolumab in Subjects With Locally Advanced/Metastatic Solid Tumors
- Where
- Shanghai
- Age
- 18 years and over
- People
- 194
- Run by
- Hefei TG ImmunoPharma Co., Ltd.
See details and how to joinNCT07376707 - Phase 1/2Taking peopleAn Phase Ib/II Clinical Trial of TCC1727 Combination Therapy in Advanced Solid Tumors
- Where
- Beijing, Hangzhou, Zhengzhou
- Age
- 18 years and over
- People
- 266
- Run by
- Beijing Tide Pharmaceutical Co., Ltd
See details and how to joinNCT07371663 - Phase 2Not yet taking people in ChinaA Prospective, Single-Arm, Phase II Clinical Study of Neoadjuvant Therapy With Pucotenlimab, Lenvatinib, and Temozolomide for Resectable Head and Neck Mucosal Melanoma (PLT-NAT-HNMM-II)
- Where
- Shanghai
- Age
- 18 years to 75 years
- People
- 30
- Run by
- Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
See details and how to joinNCT07353073 - Phase 2Not yet taking people in ChinaIparomlimab and Tuvoraleimab Injection in Combination With Bevacizumab, Albumin-bound Paclitaxel, and Carboplatin as First- or Second-line Treatment for Patients With Advanced Acral and Mucosal Melanoma
- Where
- Shanghai
- Age
- 18 years to 75 years
- People
- 48
- Run by
- Fudan University
See details and how to joinNCT07347444 - Phase 2Taking peoplePaclitaxel Polymersomes + Carboplatin + Adebelimab: Neoadjuvant Phase Ⅱ Single-Arm Study for Resectable Mucosal Melanoma
- Where
- Guangzhou
- Age
- 18 years and over
- People
- 32
- Run by
- Sun Yat-sen University
See details and how to joinNCT07336979 - Early phase 1Taking peopleA Study of GC101 TIL in Advanced Melanoma (10hospital)
- Where
- Shanghai
- Age
- 18 years to 75 years
- People
- 50
- Run by
- Shanghai Juncell Therapeutics
See details and how to joinNCT05098184 - Phase 1/2Taking peopleStudy of GV20-0251 in Participants With Solid Tumor Malignancies
- Where
- Beijing, Shanghai
- Age
- 18 years and over
- People
- 350
- Run by
- GV20 Therapeutics
See details and how to joinNCT07070518 - Phase 1Taking peopleVSV-02 Compassionate Use in Advanced Solid Tumors
- Where
- Xinxiang
- Age
- 18 years and over
- People
- 6
- Run by
- The First Affiliated Hospital of Xinxiang Medical College
See details and how to joinNCT07260591 - Phase 1Taking peopleA Study of GV20-0251 in Advanced or Refractory Solid Tumors
- Where
- Chengdu
- Age
- 18 years and over
- People
- 10
- Run by
- West China Hospital
See details and how to joinNCT07106827 - Phase 2Taking peoplePhase II Trial of Tunlametinib in Patients With NRAS Mutant Non-melanoma Refractory Solid Tumors
- Where
- Tianjin
- Age
- 18 years and over
- People
- 15
- Run by
- Tianjin Medical University Second Hospital
See details and how to joinNCT07170293